The most influential Megatrends set to shape the world through 2030, identified by Euromonitor International, help businesses better anticipate market developments and lead change for their industries.
Learn moreEuromonitor addresses your unique questions and challenges across all B2B and B2C industries and geographies through custom, tailor-made research projects, designed to your specific goals.
Learn moreOct 2019
US$990Added to Cart
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE!
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE!
Norwegian doctors are increasingly prescribing acetaminophen for their patients, leading to a proportional decline in the usage of OTC acetaminophen in relation to the total usage of acetaminophen. This prevented the higher growth of analgesics, as the demand for OTC acetaminophen was lower than it would have been without the increase in prescriptions.
Muscle and skeletal disorders are very common in Norway while the ageing population is also resulting in a rise in osteoporosis and osteoarthritis, with back pain and neck pain being very common. These ailments, along with shoulder pain, are also often caused by consumers working long and stressful hours at a desk.
Diclofenac continued to stagnate in current value terms in 2019 with it being negatively impacted by advice from the Norway Medicines Agency which advises to only use a small amount of these products when in a pill form. Studies from Denmark found links between the taking of diclofenac and cardiovascular disease.
Weifa ASA’s Paracet and Ibux brands, which dominate the acetaminophen and ibuprofen categories respectively, maintained a healthy lead in overall analgesics. Part of the reason behind their dominance is that there is a shortage of generic brands which could compete in the budget segment, as is the case in Sweden.
Weifa ASA retained its dominance in a relatively consolidated category in 2019. In addition to its leading Paracet and Ibux brands the company also offers the Proxan and Tiger Balsam brands.
GSK Consumer Healthcare is Weifa’s only significant competitor in analgesics. The company’s Voltarol brand is the only option available in diclofenac, with this coming in a gel form.
Files are delivered directly into your account within a few minutes of purchase.
Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.
Delivery: Files are delivered directly into your account within a few minutes of purchase.
Overview
Discover the latest market trends and uncover sources of future market growth for the Analgesics industry in Norway with research from Euromonitor's team of in-country analysts.
Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.
If you're in the Analgesics industry in Norway, our research will save you time and money while empowering you to make informed, profitable decisions.
The Analgesics in Norway market research report includes:
Our market research reports answer questions such as:
Why buy this report?
This industry report originates from Passport, our Consumer Health market research database.
Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.